The latest analyst update trims Inogen’s fair value estimate from $13.00 to about $12.67 per share, a reduction of roughly 2.6%. Analysts are using this adjustment alongside the recent bullish ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zacks Investment Research on MSN
Here's why you should retain Inogen stock in your portfolio for now
Inogen, Inc. INGN is well-poised for growth in the coming quarters, backed by high prospects in the portable oxygen concentrator (POC) space. The optimism, led by a diversified and expanding product ...
Zacks Investment Research on MSN
Inogen (INGN) reports Q1 loss, beats revenue estimates
Inogen (INGN) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.25 per share a year ago. These figures are adjusted ...
BEVERLY, Mass.--(BUSINESS WIRE)-- Inogen, Inc. (INGN) (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results